Capitalisation and deepened partnership with Neuraxpharm We are pleased to report that the company has successfully completed capital raise, and we would like to extend our warm thanks to you, our shareholders, for your continued [...]

Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European [...]

Dizlin Pharmaceuticals AB, a research-based pharmaceutical development company with focus on diseases of the central nervous system, today announces that the paper “Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion” was published [...]